Lexatumumab

From Wikipedia, the free encyclopedia

Lexatumumab?
Therapeutic monoclonal antibody
Source	Human
Target	TRAIL-R2
Identifiers
CAS number	?
ATC code	?
PubChem	?
Chemical data
Formula	?
Mol. mass	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Lexatumumab (also known as ETR2-ST01) is a human monoclonal antibody used to treat cancer.

[edit] External links

• Official website

v • d • e Human monoclonal antibodies ("-u-") "-limu-" (immune system) immunosuppression: Adalimumab, Atorolimumab, Gantenerumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab, Ziralimumab immune activation: Ipilimumab, Tremelimumab other: Bertilimumab "-kinu-" (interleukin as target) Canakinumab "-tumu-" (cancer immunotherapy) Adecatumumab, Anetumumab, Belimumab, Duntumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Ofatumumab, Panitumumab, Pritumumab, Votumumab, Zalutumumab, Zanolimumab "-osu-" (bone) Denosumab "-mulu-" (musculoskeletal) Durimulumab, Durmulumab, Stamulumab "-fungu-" (fungal) Efungumab "-viru-" (viral) Exbivirumab, Libivirumab, Regavirumab, Sevirumab, Tuvirumab "-bacu-" (bacterial) Nebacumab, Raxibacumab